Impact of the time interval between primary melanoma excision and sentinel node biopsy : A systematic review and meta-analysis
Copyright © 2021 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Obtaining a sentinel lymph node biopsy (SLNB) specimen is a standard staging procedure in the management of cutaneous melanoma. However, there is no consensus on the safe time interval between the primary melanoma biopsy procedure and the SLNB procedure.
OBJECTIVE: We evaluated the association between time from biopsy to SLNB and patients' outcomes for melanoma.
METHODS: We performed this systematic review and meta-analysis based on the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
RESULTS: Six retrospective studies were included. Nine thousand seven hundred five patients were identified, of which 4383 underwent a SNLB procedure at a time interval defined as early and 4574 at an interval defined as late. A combined hazard ratio of 1.25 (95% confidence interval [CI] 0.92-1.68) was determined, and there was high heterogeneity (I2 = 83%; P = .002) of the SLNB time interval on melanoma-specific survival. The combined HR for disease-free survival was 1.05 (95% CI 0.95-1.15), with low heterogeneity (I2 = 9%; P = .36). Regarding overall survival, a combined HR of 1.25 (95% CI 0.92-1.70) was found, with low heterogeneity (I2 = 37%; P = .2).
LIMITATIONS: There is heterogeneity between some studies.
CONCLUSION: There are no significant differences in patient outcome between a short interval versus a long interval between the primary biopsy procedure and obtaining a SNLB specimen.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:85 |
|---|---|
| Enthalten in: |
Journal of the American Academy of Dermatology - 85(2021), 1 vom: 15. Juli, Seite 128-134 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vargas-Mora, Pablo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Disease-free survival |
|---|
| Anmerkungen: |
Date Completed 30.08.2021 Date Revised 30.08.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jaad.2021.01.020 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320278611 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320278611 | ||
| 003 | DE-627 | ||
| 005 | 20231225173233.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaad.2021.01.020 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1067.xml |
| 035 | |a (DE-627)NLM320278611 | ||
| 035 | |a (NLM)33465429 | ||
| 035 | |a (PII)S0190-9622(21)00162-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vargas-Mora, Pablo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of the time interval between primary melanoma excision and sentinel node biopsy |b A systematic review and meta-analysis |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.08.2021 | ||
| 500 | |a Date Revised 30.08.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Obtaining a sentinel lymph node biopsy (SLNB) specimen is a standard staging procedure in the management of cutaneous melanoma. However, there is no consensus on the safe time interval between the primary melanoma biopsy procedure and the SLNB procedure | ||
| 520 | |a OBJECTIVE: We evaluated the association between time from biopsy to SLNB and patients' outcomes for melanoma | ||
| 520 | |a METHODS: We performed this systematic review and meta-analysis based on the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines | ||
| 520 | |a RESULTS: Six retrospective studies were included. Nine thousand seven hundred five patients were identified, of which 4383 underwent a SNLB procedure at a time interval defined as early and 4574 at an interval defined as late. A combined hazard ratio of 1.25 (95% confidence interval [CI] 0.92-1.68) was determined, and there was high heterogeneity (I2 = 83%; P = .002) of the SLNB time interval on melanoma-specific survival. The combined HR for disease-free survival was 1.05 (95% CI 0.95-1.15), with low heterogeneity (I2 = 9%; P = .36). Regarding overall survival, a combined HR of 1.25 (95% CI 0.92-1.70) was found, with low heterogeneity (I2 = 37%; P = .2) | ||
| 520 | |a LIMITATIONS: There is heterogeneity between some studies | ||
| 520 | |a CONCLUSION: There are no significant differences in patient outcome between a short interval versus a long interval between the primary biopsy procedure and obtaining a SNLB specimen | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a disease-free survival | |
| 650 | 4 | |a melanoma | |
| 650 | 4 | |a melanoma-specific survival | |
| 650 | 4 | |a overall survival | |
| 650 | 4 | |a sentinel lymph node biopsy | |
| 650 | 4 | |a timing of surgery | |
| 700 | 1 | |a Peruilh-Bagolini, Leonardo |e verfasserin |4 aut | |
| 700 | 1 | |a González-Cuevas, Rubén |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrer-Rosende, Pedro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the American Academy of Dermatology |d 1984 |g 85(2021), 1 vom: 15. Juli, Seite 128-134 |w (DE-627)NLM000422703 |x 1097-6787 |7 nnns |
| 773 | 1 | 8 | |g volume:85 |g year:2021 |g number:1 |g day:15 |g month:07 |g pages:128-134 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jaad.2021.01.020 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 85 |j 2021 |e 1 |b 15 |c 07 |h 128-134 | ||